



Europäisches
Patentamt

European
Patent Office

PCT/EP 03/01229
Office européen
des brevets

10/502244

REC'D 21 MAR 2003

WIPO: PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03100148.0

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

BEST AVAILABLE COPY

PCT/EP03/01229

Anmeldung Nr:
Application no.: 03100148.0
Demande no:

Anmeldetag:
Date of filing: 24.01.03
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Vlaams Interuniversitair Instituut voor
Biotechnologie vzw.
Rijvisschestraat 120
9052 Zwijnaarde
BELGIQUE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

A novel target to inhibit angiogenesis

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

A61K39/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT SE SI SK TR LI

A novel target to inhibit angiogenesis

Field of the invention

The invention relates to the field of pathological angiogenesis. In particular the invention relates to the use of molecules binding to AC133 that can be used for the manufacture of a medicament to prevent angiogenesis.

Background of the invention

The "hemangioblast" is a putative progenitor cell that has the potential to form either endothelial or hematopoietic cells. It exists during embryogenesis in the blood island region of the yolk sac (1), which is therefore the earliest site of hematopoiesis and vasculogenesis. Until recently, vasculogenesis has been thought to be restricted to the yolk sac and the early embryogenesis. However, novel observations have revealed in adulthood a situation consistent with vasculogenesis: endothelial cells derived from angioblasts or "hemangioblasts" previously isolated from peripheral blood or bone marrow are incorporated into sites of neovascularization in physiological and pathological conditions (2-6). In addition, the number of these endothelial cell progenitors increases in the peripheral blood during tissue ischemia or following the administration of VEGF or GM-CSF, a cytokine known to induce mobilization of hematopoietic stem cells from the bone marrow into the peripheral blood (5, 6). Recent studies in humans, dogs, rats, rabbits and mice have indeed indicated the presence of endothelial precursor cells (EPCs) in bone marrow and peripheral blood during adult life which can be mobilized and incorporated into newly formed vessels or are involved in endothelialization of implants (4, 7-13). Interestingly, in all these experiments, EPCs are isolated together with other hematopoietic stem cells by using antibodies directed against hematopoietic stem cell antigens. AC133 is a rather novel human hematopoietic stem cell antigen (14) of unknown physiological or pathological function. AC133, recently designed CD133 (National Center for Biotechnology, 2000) is expressed on lineage non-committed stem and progenitor cells but not on mature peripheral blood cells and umbilical vein derived endothelial cells (15). It is detected on 30-60% of all CD34⁺ cells, including CD34^{bright} cells. This cell population contains CD38^{dim/neg}, HLA-DR⁻, CD117⁺, CD90⁺ cells. AC133⁺ CD34⁺ hematopoietic stem cells

are enriched in Long-Term Culture-Initiating Cells, NOD/SCID repopulating cells and dendritic cell progenitors (16). Subsets of this population express the angiopoietin receptors TIE (67.6%) and TEK (36.8%), Flt-1 (7%), Flt-4 (3.2%), KDR (10.4%), the receptor tyrosine kinase HER-2 (15.4%) and Flt-3 (77.6%). Only few AC133⁺ cells do not co-express CD34: these cells are very small and define a population of unknown delineation (CD71⁻, CD117⁻, CD10⁻, CD38^{low}, CD135⁺, HLA-DR^{high}) (17). In acute myeloid leukemias, AC133 expression is often but not always associated with CD34 expression (18, 19). AC133 is also found on acute lymphoid leukemia blasts and on a subset of CD34⁺ B-cell precursors (20). Flow cytometric analyses of a wide panel of human cell lines showed that only retinoblastoma and teratocarcinoma cell lines express AC133 (21). Recently, AC133 was found to be expressed in EPCs. CD34⁺ cells co-expressing VEGFR-2 and AC133 have been isolated from peripheral blood, cord blood, fetal liver and bone marrow. However, the possible role of AC 133 in hematopoiesis and vasculogenesis in the developing embryo and, after birth, in angiogenesis, postnatal vasculogenesis and hematopoietic stem cell trafficking, remains largely unknown. To study in detail the *in vivo* role of AC133 in the present invention AC133 deficient mice were generated. It was surprisingly found that AC 133 has a key role in pathological vasculogenesis and/or angiogenesis and that inhibitors of AC133 can be used in therapeutic strategies to inhibit blood vessel formation in various pathological disorders.

Aims and detailed description of the invention

AC133 is a protein of 97 KD with a 5-transmembrane structure (14). The 5-transmembrane structure appears at present restricted to the human AC133, the murine prominin and the related protein of the nematode *C. elegans* (25-28). This structure indicates that these proteins belong to a new class of serpentine receptors. Murine prominin has 60% amino acid homology with AC133 (25). It is not yet clear whether murine prominin is the murine homologue of human AC133, or whether it is a close family member (25, 26). For the sake of clarity the nucleotide sequence of human AC133 is designated here as SEQ ID NO: 1 and the amino acid sequence of human AC133 is designated as SEQ ID NO: 2. The present invention shows that inhibitors of AC133 can be used in therapeutic applications for the prevention of pathological angiogenesis.

Thus the invention provides in one embodiment the use of a molecule which comprises a region specifically binding to AC133 or nucleic acids encoding AC133, for the manufacture of a medicament to treat pathological angiogenesis.

- 5 According to the invention molecules that comprise a region specifically binding to AC133 or nucleic acids encoding AC133 which can be used for the manufacture of a medicament to treat pathological angiogenesis can be chosen from the list comprising an antibody or any fragment thereof binding to AC133, a (synthetic) peptide, a protein, a small molecule specifically binding to AC133 or nucleic acids encoding AC133, a
10 ribozyme against nucleic acids encoding AC133, and anti-sense nucleic acids hybridising with nucleic acids encoding AC133.

The term 'antibody' or 'antibodies' relates to an antibody characterized as being specifically directed against AC133 or any functional derivative thereof, with said
15 antibodies being preferably monoclonal antibodies; or an antigen-binding fragment thereof, of the F(ab')₂, F(ab) or single chain Fv type, or any type of recombinant antibody derived thereof. These antibodies of the invention, including specific polyclonal antisera prepared against AC133 or any functional derivative thereof, have no cross-reactivity to others proteins. The monoclonal antibodies of the invention can
20 for instance be produced by any hybridoma liable to be formed according to classical methods from splenic cells of an animal, particularly of a mouse or rat immunized against AC133 or any functional derivative thereof, and of cells of a myeloma cell line, and to be selected by the ability of the hybridoma to produce the monoclonal antibodies recognizing AC133 or any functional derivative thereof which have been
25 initially used for the immunization of the animals. The monoclonal antibodies according to this embodiment of the invention may be humanized versions of the mouse monoclonal antibodies made by means of recombinant DNA technology, departing from the mouse and/or human genomic DNA sequences coding for H and L chains or from cDNA clones coding for H and L chains. Alternatively the monoclonal
30 antibodies according to this embodiment of the invention may be human monoclonal antibodies. Such human monoclonal antibodies are prepared, for instance, by means of human peripheral blood lymphocytes (PBL) repopulation of severe combined immune deficiency (SCID) mice as described in PCT/EP 99/03605 or by using transgenic non-human animals capable of producing human antibodies as described

in US patent 5,545,806. Also fragments derived from these monoclonal antibodies such as Fab, F(ab)₂ and ssFv ("single chain variable fragment"), providing they have retained the original binding properties, form part of the present invention. Such fragments are commonly generated by, for instance, enzymatic digestion of the antibodies with papain, pepsin, or other proteases. It is well known to the person skilled in the art that monoclonal antibodies, or fragments thereof, can be modified for various uses. The antibodies involved in the invention can be labeled by an appropriate label of the enzymatic, fluorescent, or radioactive type.

In a specific embodiment the antibodies against AC133 can be derived from animals of the camelid family. In said family immunoglobulins devoid of light polypeptide chains are found. Heavy chain variable domain sequences derived from camelids are designated as VHH's. "Camelids" comprise old world camelids (*Camelus bactrianus* and *Camelus dromaderius*) and new world camelids (for example *Lama paccos*, *Lama glama* and *Lama vicugna*). EP0656946 describes the isolation and uses of camelid immunoglobulins and is incorporated herein by reference.

Small molecules, e.g. small organic molecules, and other drug candidates can be obtained, for example, from combinatorial and natural product libraries.

Also within the scope of the invention are oligoribonucleotide sequences, that include anti-sense RNA and DNA molecules and ribozymes that function to inhibit the translation of AC133 mRNA. Anti-sense RNA and DNA molecules act to directly block the translation of mRNA by binding to targeted mRNA and preventing protein translation. In regard to antisense DNA, oligodeoxyribonucleotides derived from the translation initiation site, e.g., between -10 and +10 regions of the AC133 nucleotide sequence, are preferred. Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of AC133 RNA sequences.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of

between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.

Both anti-sense RNA and DNA molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides well known in the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize anti-sense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

The term 'pathological angiogenesis' refers to the formation and growth of blood vessels during the maintenance and the progression of several disease states.

Examples where pathological angiogenesis can occur are blood vessels (atherosclerosis, hemangioma, hemangioendothelioma), bone and joints (rheumatoid arthritis, synovitis, bone and cartilage destruction, osteomyelitis, pannus growth, osteophyte formation, neoplasms and metastasis), skin (warts, pyogenic granulomas, hair growth, Kaposi's sarcoma, scar keloids, allergic oedema, neoplasms), liver, kidney, lung, ear and other epithelia (inflammatory and infectious processes (including hepatitis, glomerulonephritis, pneumonia), asthma, nasal polyps, otitis, transplantation, liver regeneration, neoplasms and metastasis), uterus, ovary and placenta (dysfunctional uterine bleeding (due to intrauterine contraceptive devices), follicular cyst formation, ovarian hyperstimulation syndrome, endometriosis, neoplasms), brain, nerves and eye (retinopathy of prematurity, diabetic retinopathy, choroidal and other intraocular disorders, leukomalacia, neoplasms and metastasis), heart and skeletal muscle due to work overload, adipose tissue (obesity), endocrine organs (thyroiditis, thyroid enlargement, pancreas transplantation), hematopoiesis (AIDS (Kaposi),

hematologic malignancies (leukemias, etc.), lymph vessels (tumour metastasis, lymphoproliferative disorders).

5 The term 'medicament to treat' relates to a composition comprising molecules as described above and a pharmaceutically acceptable carrier or excipient (both terms can be used interchangeably) to treat diseases as indicated above. Suitable carriers or excipients known to the skilled man are saline, Ringer's solution, dextrose solution, Hank's solution, fixed oils, ethyl oleate, 5% dextrose in saline, substances that enhance isotonicity and chemical stability, buffers and preservatives. Other suitable
10 carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids and amino acid copolymers. The 'medicament' may be administered by any suitable method within the knowledge of the skilled man. The preferred route of administration is parenterally. In parental
15 administration, the medicament of this invention will be formulated in a unit dosage injectable form such as a solution, suspension or emulsion, in association with the pharmaceutically acceptable excipients as defined above. However, the dosage and mode of administration will depend on the individual. Generally, the medicament is administered so that the protein, polypeptide, peptide of the present invention is given
20 at a dose between 1 $\mu\text{g/kg}$ and 10 mg/kg , more preferably between 10 $\mu\text{g/kg}$ and 5 mg/kg , most preferably between 0.1 and 2 mg/kg . Preferably, it is given as a bolus dose. Continuous infusion may also be used and includes continuous subcutaneous delivery via an osmotic minipump. If so, the medicament may be infused at a dose between 5 and 20 $\mu\text{g/kg/minute}$, more preferably between 7 and 15 $\mu\text{g/kg/minute}$.

25 In another embodiment antibodies or functional fragments thereof can be used for the manufacture of a medicament for the treatment of the above mentioned disorders. As a non-limiting example there are the antibodies described in US 5,843,633. In a specific embodiment said antibodies are humanized (Rader et al., 2000, J. Biol. Chem. 275, 13668) and more specifically human antibodies are used to manufacture a
30 medicament to treat pathological angiogenesis. In yet another specific embodiment antibodies derived from camelids are used to manufacture a medicament to treat pathological angiogenesis.

Another aspect of administration for treatment is the use of gene therapy to deliver the above mentioned anti-sense gene or functional parts of the AC133 gene or a ribozyme directed against the AC133 mRNA or a functional part thereof. Gene therapy means the treatment by the delivery of therapeutic nucleic acids to patient's cells. This is extensively reviewed in Lever and Goodfellow 1995; Br. Med Bull.,51, 1-242; Culver 1995; Ledley, F.D. 1995. Hum. Gene Ther. 6, 1129. To achieve gene therapy there must be a method of delivering genes to the patient's cells and additional methods to ensure the effective production of any therapeutic genes. There are two general approaches to achieve gene delivery; these are non-viral delivery and virus-mediated gene delivery.

The invention also provides methods for identifying compounds or molecules which bind on AC133 and prevent or suppress pathological angiogenesis. With "suppression" it is understood that said suppression can occur for at least 20%, 30%, 30%, 50%, 60%, 70%, 80%, 90% or even 100%.

Thus in another embodiment the invention provides a method to identify molecules that comprise a region that specifically binds to AC133 comprising: (1) exposing AC133 or nucleic acids encoding AC133 to at least one molecule whose ability to suppress or prevent pathological angiogenesis is sought to be determined, (2) determining binding or hybridising of said molecule(s) to AC133 or nucleic acids encoding AC133, and (3) monitoring said pathological angiogenesis when administering said molecules as a medicament.

The latter method is also referred to as 'drug screening assay' or 'bioassay' and typically include the step of screening a candidate/test compound or agent for the ability to interact with AC133. Candidate compounds or agents, which have this ability, can be used as drugs to combat or prevent pathological conditions of angiogenesis. Candidate/test compounds such as small molecules, e.g. small organic molecules, and other drug candidates can be obtained, for example, from combinatorial and natural product libraries as described above.

Typically, the assays are cell-free assays which include the steps of combining AC133 and a candidate/test compound, e.g., under conditions which allow for interaction of (e.g. binding of) the candidate/test compound with AC133 to form a complex, and detecting the formation of a complex, in which the ability of the candidate compound to

interact with AC133 is indicated by the presence of the candidate compound in the complex. Formation of complexes between AC133 and the candidate compound can be quantitated, for example, using standard immunoassays. The AC133 employed in such a test may be free in solution, affixed to a solid support, borne on a cell surface, or located extracellularly or even intracellularly.

To perform the above described drug screening assays, it is feasible to immobilize AC133 or its (their) target molecule(s) to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Interaction (e.g., binding of) of AC133 to a target molecule, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and microcentrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, AC133-His tagged can be adsorbed onto Ni-NTA microtitre plates, or AC133-ProtA fusions adsorbed to IgG, which are then combined with the cell lysates (e.g., ³⁵S-labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the plates are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of AC133-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. Other techniques for immobilizing protein on matrices can also be used in the drug screening assays of the invention. For example, AC133 can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated AC133 can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Another technique for drug screening which provides for high throughput screening of compounds having suitable binding affinity to AC133 is described in detail in "Determination of Amino Acid Sequence Antigenicity" by Geysen HN, WO 84/03564, published on 13/09/84. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The protein test compounds are reacted with fragments of AC133 and washed. Bound AC133 is then detected by methods well known in the art. Purified

AC133 can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support. This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding AC133 specifically compete with a test compound for binding AC133. In this manner, the antibodies can be used to detect the presence of any protein, which shares one or more antigenic determinants with AC133.

Examples

10 1. Generation of a AC133 knock-out mouse

Targeted inactivation of the *AC133* gene was achieved by deletion of exon 2 (containing the start codon). Briefly, a genomic BAC (bacterial artificial chromosome) containing the murine *AC133* (14) was obtained from Research Genetics Inc (Huntsville, AL) after screening by PCR and hybridization. Mapping of the murine *AC133* homologue gene revealed that the first exon, which is 79 bp long, is separated from the second exon by an approximately 8 kb intron. It is the second exon (376 bp long) which contains the startcodon ATG. A BamHI fragment of 11.5 kb containing exon 2 was subcloned into the pUC18 plasmid. A targeting vector for inactivation of the *AC133* gene, *pPNT.AC133^{null}*, was constructed consisting of, from 5' to 3': 1.2 kb of 5' homology comprising the end of intron 1; a *loxP*-flanked *neomycin* gene; 5.5 kb from intron 2 as 3'-homology; and a *thymidine kinase* selection cassette outside of the regions of homology for counterselection against random integration events. The integrity of the construct was verified by restriction digestion and sequencing. The linearized targeting vector *pPNT.AC133^{null}* was electroporated in R1 ES cells and targeted clones were identified by appropriate Southern blot analysis and used for morula aggregation to generate AC133 deficient chimeric and germline mice. AC133^{-/-} mice were born at the expected Mendelian frequency (~25% of 450 offspring from AC133^{+/-} breeding pairs). They appeared healthy and were fertile, irrespective of their genetic background (backgrounds tested: 50% Swiss/50% 129, 100% 129, 50% C57Bl6/50% 129 and 50% NMRI/50% 129). We anticipated that AC133 might play a crucial role in hematopoiesis implying that the AC133^{-/-} embryo would die *in utero* either after the appearance of the primitive hematopoiesis (7.5 days post coitum, site:

yolk sac) or at the emergence of the definitive hematopoiesis (12.5 days post coitum, site: fetal liver). Surprisingly, however, embryonic development in AC133^{-/-} mice was normal. AC133^{-/-} embryos were not rescued by maternal AC133, as AC133^{-/-} embryos, sired by AC133^{+/-} as well as by AC133^{-/-} breeding pairs, developed normally. Also postnatal physiological vascular development seemed normal since no vascular defects could be observed in the heart, kidneys, lungs and skeletal muscle during postnatal growth in AC133^{-/-} mice.

2. Impaired pathological angiogenesis in AC133 knock-out mice

In order to study the possible role of AC133 in pathological conditions of angiogenesis AC133^{-/-} mice and their wild-type littermates were subjected to a mouse model of ischemic retinopathy. In this hyperoxia-induced retinopathy model, neonatal mice (with an immature retinal vasculature) are exposed to hyperoxia, resulting in obliteration of the developing blood vessels supplying oxygen to the retina. When the mice are then returned to normoxia, the retina, distal to the occluded vessels, becomes ischemic, inducing VEGF production and ultimately resulting in reproducible and quantifiable proliferative retinal neovascularization (29, 30). This model, which mimicks to a certain extent the vascular response during retinopathy of prematurity or diabetic retinopathy, may be useful to test the efficacy of (anti)-angiogenic molecules (31). Mouse pups of 7 days (P7) together with their mothers, are subjected to hyperoxia (75% oxygen) in specially designed oxygen chambers for 5 days, without opening the cages. On P12, the animals are returned to room air until P17, when the retinas are assessed for maximal neovascular response. Anesthetized mice are perfused through the left ventricle with 1 ml of phosphate buffered saline containing 50 mg of 2x10⁶ molecular weight fluorescein-dextran. The eyes are removed and fixed in 4% paraformaldehyde for 3 (right eye) or 24 (left eye) hrs. Of the right eyes, lenses are removed and peripheral retinas cut to allow flat mounting with glycerol-gelatin. The flat mounted retinas are analyzed by fluorescence microscopy. The left eyes are embedded in paraffin and serial 6 µm sections are cut sagittally throughout the cornea, parallel to the optic nerve, and stained with hematoxylin-eosin. The proliferative neovascular response is quantified by counting the number of new vessels (= tufts) and the number of endothelial cells extending from the internal limiting membrane of the retina into the vitreum on the stained sagittal cross-sections. The angiographic technique using

fluorescein-dextran perfusion is used in conjunction with this counting method for rapid screening of retinas or as an alternative grading system for quantitative evaluation.

Loss of AC133 significantly protected mice against intra-vitreous neovascularization, as evaluated by counting the number of neovascular tufts and endothelial cells (EC) in the vitreous cavity (n=15; p<0.001)

| | N° of tufts in vitreous cavity (per 10 retinal sections) | N° of EC in vitreous cavity (per 10 retinal sections) |
|------------------------------------|---|--|
| AC133 ^{+/+} pups (n = 15) | 157.1 ± 13.6 | 286.0 ± 45.1 |
| AC133 ^{-/-} pups (n = 15) | 72.5 ± 14.6 | 106.2 ± 22.6 |

The effect of (anti)-angiogenic molecules has been frequently studied in the corneal micropocket assay [Kenyon, 1996]. Implantation of hydon pellets containing angiogenic factors in the stroma of the avascular mouse cornea allows screening of the angiogenic response in the absence of inflammation. As the cornea in the mouse is thinner than in other species, growth of new blood vessels largely occurs in a two-dimensional plane. Hydon pellets containing an angiogenic substance (like bFGF or VEGF) are implanted into the corneal stroma adjacent to the temporal limbus. This induces neovascularization of the avascular corneal stroma from day 3 to day 8 after implantation, without substantial corneal edema or inflammation. Like the retinal hypoxia model, it gives a predictable, persistent and aggressive neovascular response, which is dependent on direct stimulation of blood vessels rather than on indirect stimulation by the induction of inflammation [Kenyon, 1996]. The mouse corneal micropocket assay was performed as previously described [Asahara, 1998]. Hydon-coated sucralfate pellets containing 300 ng of VEGF₁₆₅ were positioned 1 mm from the corneal limbus. Corneal angiogenesis was evaluated six days after implantation of hydon pellets. Anesthetized mice were perfused through the left ventricle with 1 ml of phosphate buffered saline containing 50 mg of 2x10⁶ molecular weight fluorescein-dextran. The eyes were removed and fixed in 4% paraformaldehyde for 3 hrs. Corneas were peeled of and flat mounted with glycerol-gelatin. Vessel length, the arc of circumference occupied by neovascularity

(circumferential neovascularity) and the integrated optical density of the area occupied by new vessels was determined by fluorescence microscopy and image analysis.

Mice deficient for AC133 showed a reduced angiogenic response. Despite a comparable length of the newly formed vessels, the circumferential neovascularity and the integrated optical density of the vessel area were significantly lower in the AC133 mice (n=7; p<0.05).

| | Vessel length (μm) | Circumferential neovascularity (μm) | Integrated optical density of the vessel area |
|-----------------------------------|---------------------------------|--|---|
| AC133 ^{+/+} pups (n = 7) | 5.3 \pm 0.6 | 41.7 \pm 3.0 | 430 \pm 58 |
| AC133 ^{-/-} pups (n = 7) | 5.1 \pm 0.7 | 28.9 \pm 3.5 * | 302 \pm 37 * |

Vascular remodeling was also studied in a model of skin wound healing as described before [Frank, 1995; Carmeliet, 2001]. For skin wounding, a standardised 15 mm full-thickness skin incision was made on the back of the mice, taking care not to damage the underlying muscle. Wound healing was quantified by daily measurements of the width and the length of the wound. New blood vessel formation was analysed on skin sections harvested four days after wounding. Using antibodies to CD31, which labels endothelial cells, and antibodies to smooth muscle alpha actin, labeling smooth muscle cells, the number of new vessels and of new vessels covered with SMC were analysed. Both genotypes contained comparable densities of vessels in unwounded skin. However, the number of capillaries infiltrating the wound as well as the number of smooth muscle-coated vessels in the wounded area were significantly reduced in AC133 deficient mice (n=5; p<0.05).

| | Capillary density in wounded area (/ mm^2) | Density of SMC coated vessels (/ mm^2) |
|-----------------------------------|--|--|
| AC133 ^{+/+} pups (n = 5) | \pm | 53.4 \pm 5.9 |
| AC133 ^{-/-} pups (n = 5) | \pm | 28.6 \pm 2.7 * |

The role of PROM-1 in pathological vasculogenesis and angiogenesis

General introduction

Prominin-1 (PROM-1), also called AC133 or CD133, is a rather novel human
 5 hematopoietic stem cell antigen ¹ of unknown physiological or pathological function. AC133-antigen was first detected on CD34^{bright} hematopoietic stem cells ² and has since been widely used to facilitate the analysis and isolation of hematopoietic and primitive cells ³⁻⁵. Only few AC133⁺ cells do not coexpress CD34: these cells are very small and define a population of unknown delineation ⁶. In acute myeloid leukemias,
 10 PROM-1 expression is often but not always associated with CD34 expression ^{7,8}. AC133 is also found on acute lymphoid leukemia blasts and on a subset of CD34⁺ B-cell precursors ⁹. Flow cytometry analyses of a wide panel of human cell lines showed that only retinoblastoma and teratocarcinoma cell lines express AC133¹⁰. More recently, it was shown that endothelial progenitor cells co-express PROM-1 antigen
 15 and the endothelial cell-specific receptor kinase-inert domain-containing acceptor (KDR) in subpopulations of CD34⁺ cells derived from fetal liver, bone marrow, cord blood and peripheral blood ^{11,12}. Recently, human central nervous system stem cells were also reported to express AC133-antigen ¹³. A characteristic feature of this protein is its rapid down-regulation during cell differentiation ^{12,14}, which makes it a
 20 unique cell surface marker for the identification and isolation of stem cells and progenitor cells.

Human PROM-1 antigen is a glycoprotein of 120 KD and contains an extracellular N terminus, two extracellular loops, five transmembrane domains, two small cysteine-rich cytoplasmic loops and a cytoplasmic C terminus ¹. Recently a novel isoform of
 25 human PROM-1 with a 27 basepair deletion has been described ¹⁵. A structural and sequence-related protein, was identified as the mouse orthologue of human PROM-1 ¹⁴. The 5-transmembrane structure appears phylogenetically conserved from mammals to zebrafish and in fruit flies and nematodes ^{16,17}. Murine prominin, which has a 65% amino acid homology with human PROM-1 also exists in two isoforms.
 30 The short human and murine prominin isoform both encode proteins that lack a 9-amino acid segment at the same location in the N-terminal extracellular region just proximal to the first transmembrane domain ^{15,18,19}.

Although human PROM-1 has been used as a cell surface marker to identify and isolate certain stem cell and progenitor cell populations, the molecular mechanism of how this protein functions remain unclear. To study the in vivo role of PROM-1 in hematopoiesis, vasculogenesis, angiogenesis and possibly neurogenesis, we generated PROM-1 deficient mice.

The role of PROM-1 in blood vessel formation

Background and significance

The "hemangioblast" is a putative progenitor cell that has the potential to form either endothelial or hematopoietic cells. It exists during embryogenesis in the blood island region of the yolk sac ²⁰, which is therefore the earliest site of hematopoiesis and vasculogenesis. Until recently, vasculogenesis has been thought to be restricted to the yolk sac and the early embryogenesis. However, novel observations have revealed in adulthood a situation consistent with vasculogenesis: endothelial cells derived from angioblasts or "hemangioblasts" previously isolated from peripheral blood or bone marrow are incorporated into sites of neovascularization in physiological and pathological conditions ²¹⁻²⁵. In addition, the number of these endothelial cell progenitors increases in the peripheral blood during tissue ischemia or following the administration of VEGF or GM-CSF, a cytokine known to induce mobilization of hematopoietic stem cells from the bone marrow into the peripheral blood ^{24,25}. Recent studies in humans, dogs, rats, rabbits and mice have indeed indicated the presence of endothelial precursor cells (EPCs) in bone marrow and peripheral blood during adult life which can be mobilized and incorporated into newly formed vessels or are involved in endothelialization of implants ^{23,26-32}.

Interestingly, in all these experiments, endothelial cell progenitors are isolated together with other hematopoietic stem cells by using antibodies directed against hematopoietic stem cell antigens. PROM-1 is expressed on lineage non-committed stem and progenitor cells but not on mature peripheral blood cells and umbilical vein derived endothelial cells ². CD34⁺ cells co-expressing VEGFR-2 and PROM-1, recently designed CD133 (National Center for Biotechnology, 2000) have been isolated from peripheral blood, cord blood, fetal liver and bone marrow. When grown in the presence of VEGF and FGF-2 or the novel cytokine stem cell growth factor

(SCGF), these cells give rise to endothelial cells, thus suggesting that this subset of CD34⁺, VEGFR-2⁺ & CD133⁺ cells may play a role in neovasculogenesis^{3,5,11}.

Long term objectives

1. To study the possible role of PROM-1 in hematopoiesis and vasculogenesis in the developing embryo.
2. To determine a possible role for PROM-1 in postnatal vasculogenesis, angiogenesis and hematopoietic stem cell trafficking, in pathological conditions of blood vessel formation.

Preliminary results

➤ To study the *in vivo* role of PROM-1, PROM-1 (prominin) deficient mice were generated. Targeted inactivation of the PROM-1 gene was achieved by deletion of exon 2 (containing the start codon). Briefly, a genomic BAC (bacterial artificial chromosome) containing the murine PROM-1¹ was obtained from Research Genetics Inc (Huntsville, AL) after screening by PCR and hybridization. Mapping of the murine PROM-1 homologue gene revealed that the first exon, which is 79 bp long, is separated from the second exon by an approximately 8 kb intron. It is the second exon (376 bp long) that contains the startcodon ATG. A BamHI fragment of 11.5 kb containing exon 2 was subcloned into the pUC18 plasmid. A targeting vector for inactivation of the PROM-1 gene, pPNT.PROM-1^{null}, was constructed consisting of, from 5' to 3': 1.2 kb of 5' homology comprising the end of intron 1; a *loxP*-flanked *neomycin* gene; 5.5 kb from intron 2 as 3'-homology; and a *thymidine kinase* selection cassette outside of the regions of homology for counterselection against random integration events. The integrity of the construct was verified by restriction digestion and sequencing. The linearized targeting vector pPNT.PROM-1^{null} was electroporated in R1 ES cells and targeted clones were identified by appropriate Southern blot analysis and used for morula aggregation to generate PROM-1 deficient chimeric and germline mice.

➤ PROM-1 deficient mice were born at the expected Mendelian frequency (~25% of 450 offspring from PROM-1 heterozygous breeding pairs). They appeared healthy and were fertile, irrespective of their genetic background (backgrounds tested: 50% Swiss/50% 129, 100% 129, 50% C57Bl6/50% 129). We anticipated that PROM-1 might play a crucial role in hematopoiesis implying that the PROM-1^{-/-} embryo would die *in utero* either after the appearance of the

primitive hematopoiesis (7.5 days post coitum, site: yolk sac) at the emergence of the definitive hematopoiesis (12.5 days post coitum, site: fetal liver). Surprisingly, however, embryonic development in PROM-1^{-/-} mice was normal. PROM-1^{-/-} embryos were not rescued by maternal PROM-1, as PROM-1^{-/-} embryos, sired by PROM-1^{+/-} as well as by PROM-1^{-/-} breeding pairs, developed normally. Also postnatal physiological vascular development seemed normal since no vascular defects could be observed in the heart (capillary density is 5810 ± 154 in PROM-1^{+/-} pups versus 5394 ± 179 in PROM-1^{-/-} pups, n=3; p=NS), kidneys (number of glomeruli), lungs and skeletal muscle during postnatal growth in PROM-1^{-/-} mice.

➤ In order to study the possible role of PROM-1 in pathological conditions of angiogenesis AC 133^{-/-} mice and their wild-type littermates are or will be subjected to various murine models of pathological blood vessel formation.

Hyperoxia-induced retinopathy model: Neonatal mouse pups of 7 days (P7) (with an immature retinal vasculature) are exposed to hyperoxia (75% oxygen) for 5 days, resulting in obliteration of the developing blood vessels supplying oxygen to the retina. When the mice are then returned to normoxia, the retina becomes ischemic, inducing VEGF production and ultimately resulting in reproducible and quantifiable proliferative neovascularization in the vitreous cavity^{33,34}. Preliminary results showed that loss of PROM-1 significantly protected mice against intravitreal neovascularization, as evaluated by counting the number of neovascular tufts in the vitreous cavity (157.1 ± 13.6 in PROM-1^{+/-} pups versus 72.5 ± 14.6 in PROM-1^{-/-} pups, n=15; p<0.001).

However, since it has been published recently, that a mutation in PROM-1 in human causes retinal degeneration possibly because of impaired regeneration of the evaginations and/or impaired conversions of the evaginations to disks¹⁶, we started to look for retinal degeneration in our PROM-1 deficient mice. Retinal degeneration was indeed observed at 100% incidence in PROM-1 deficient mice even at young age (P21) (n= 4 for P21 and n= 3 for adult mice). Semithin sections clearly revealed that the photoreceptor layer, containing the rods and cones, and the outer nuclear layer are significantly reduced. Immunostainings in the retina showed that GFAP (astrocytes & Muller cells) and vimentin (Muller cells) expression were significantly upregulated in the PROM-1 deficient mice.

Less NSE and rhodopsin immunopositive photoreceptor cells were found in the photoreceptor and in the outer nuclear layer, while the number of CD90 positive ganglion cells in the ganglion cell layer, the number of syntaxin-1 amacrine cells in the inner plexiform layer and the number of PKC positive bipolar cells in the outer plexiform layer were identical in the two genotypes.

Corneal micropocket assay: Hydron pellets containing an angiogenic substance (like bFGF or VEGF) are implanted into the corneal stroma adjacent to the temporal limbus. This induces neovascularization of the avascular corneal stroma from day 3 to day 8 after implantation, without substantial corneal edema or inflammation. Like the retinal hypoxia model, it gives a predictable, persistent and aggressive neovascular response, which is dependent on direct stimulation of blood vessels rather than on indirect stimulation by the induction of inflammation³⁵. The mouse corneal micropocket assay was performed as previously described³⁶. Mice deficient for PROM-1 showed a reduced angiogenic response. The length of the newly formed vessels (0.93 ± 0.12 mm in PROM-1^{+/+} mice versus 0.70 ± 0.03 mm in PROM-1^{-/-} mice, n=6; p<0.005) as well as the circumferential neovascularity (6.23 ± 0.55 mm in PROM-1^{+/+} mice versus 3.60 ± 0.32 mm in PROM-1^{-/-} mice, n=6; p<0.005) and the integrated optical density of the vessel area (497 ± 100 in PROM-1^{+/+} mice versus 196 ± 27 in PROM-1^{-/-} mice, n=6; p<0.05) were significantly lower in the PROM-1 mice. Moreover, WT bone marrow transplantation into PROM-1 deficient mice rescued the impaired angiogenic response. The length of the newly formed vessels (0.57 ± 0.03 mm in PROM-1^{+/+} mice versus 0.57 ± 0.03 mm in PROM-1^{-/-} mice, n=6; p<0.005) as well as the circumferential neovascularity (3.52 ± 0.26 mm in PROM-1^{+/+} mice versus 3.29 ± 0.22 mm in PROM-1^{-/-} mice, n=6; p=NS) were identical in the both PROM-1 deficient and WT mice after WT bone marrow transplantation.

Model of skin wound healing: Vascular remodeling was also studied in a model of skin wound healing as described before^{37,38}. For skin wounding, a standardised 15 mm full-thickness skin incision was made on the back of the mice, taking care not to damage the underlying muscle. Wound healing was quantified by daily measuring the width and the length of the wound. New blood vessel formation was analysed on skin sections harvested four days after wounding.

Wound healing was significantly impaired in the PROM-1 deficient mice as shown by the figure below. Both genotypes contained comparable densities of vessels in unwounded skin. However, the number of capillaries infiltrating the wound (185.8 ± 11.1 vessels/mm² in PROM-1^{+/+} mice versus 135.0 ± 12.7 in PROM-1^{-/-} mice, n=5; p<0.05), as well as the number of smooth muscle-coated vessels in the wounded area (58.2 ± 10 vessels/mm² in PROM-1^{+/+} mice versus 28.6 ± 4.022 in PROM-1^{-/-} mice, n=5; p<0.05) were significantly reduced in PROM-1 deficient mice.

Matrigel assay: Ingrowth of capillaries was also studied in a matrigel assay performed as described³⁹. The angiogenic response in the matrigel of PROM-1^{-/-} mice seemed somewhat lower as measured by the hemoglobin content per matrigel implant (137.0 ± 20.4 µg/ml in PROM-1^{+/+} mice versus 112.1 ± 17.6 µg/ml in PROM-1^{-/-} mice; n=15; p= NS). Histological sections of matrigel were then analysed for infiltration of leukocytes and for blood vessel formation after staining for inflammatory cells (CD45) and endothelial cells (CD31), respectively. The number of infiltrating leukocytes did not seem to differ but a reduced blood vessel formation (CD31 positive endothelial cells) was noticed in the matrigel implanted in PROM-1 deficient animals (% of CD31 positive area in matrigel: $0.55 \pm 0.08\%$ in PROM-1^{+/+} mice versus $0.26 \pm 0.06\%$ in PROM-1^{-/-} mice; n=5; p<0.05).

Myocardial infarction model: Myocardial infarction was performed by ligation of the LAD as described⁴⁰. After 4 to 7 days, infarcted hearts were used for histological analysis or for immunostaining of thrombomodulin (endothelial cells) or smooth muscle alpha-actin (smooth muscle cells)³⁸. Morphometric analysis and counting of immunoreactive cells was performed using a Quantimet Q600 image analysis system (Leica, Brussels, Belgium).

No differences were observed in the number of capillaries at 4 (490.9 ± 65.4 vessels/mm² in PROM-1^{+/+} mice versus 493.3 ± 87.7 vessels/mm² in PROM-1^{-/-} mice; n=3; p= NS) or 7 days (510.6 ± 28.3 vessels/mm² in PROM-1^{+/+} mice versus 507.8 ± 24.6 vessels/mm² in PROM-1^{-/-} mice; n=10; p= NS) after ligation or in the number of SMC covered vessels at 4 (20.3 ± 3.2 vessels/mm² in PROM-1^{+/+} mice versus 23.3 ± 6.73 vessels/mm² in PROM-1^{-/-} mice; n=3; p= NS) or at 7

days (87.6 ± 14.3 vessels/mm² in PROM-1^{+/+} mice versus 76.4 ± 12.2 vessels/mm² in PROM-1^{-/-} mice; n=10; p= NS) in the infarcted area of hearts of PROM-1 deficient mice and wild-type littermates. However, a clear significant difference was observed in the number of infiltrating macrophages at 7 days after ligation (% of Mac3 positive area: 3.75 ± 0.77 % in PROM-1^{+/+} mice versus 1.62 ± 0.42 % in PROM-1^{-/-} mice; n=10; p< 0.05).

Hind limb ischemia model: Hind limb ischemia will be induced as described ⁴¹. Unilateral right or bilateral ligations of the femoral artery and vein (proximal to the popliteal artery) and the cutaneous vessels branching from the caudal femoral artery side branch will be performed and two superficial preexisting collateral arterioles, connecting the femoral and saphenous artery, will be used for analysis. Genetic consequences on post-ischemic revascularization will be determined 14 days after ligation, using vascular morphological (histological evaluation of capillary density and SMC-coated vessel density, histological evaluation of myocyte necrosis and regeneration), perfusional (fluorescent microspheres, laser Doppler imaging), and functional (graded treadmill exercise or swim endurance exercise) analyses.

In a first experiment, no differences were found in the number or size of the main collateral or its second and third side branches in the adductor muscles of PROM-1 deficient and wild-type animals. We could not observe any genotypic differences in blood flow, measured by using fluorescent microspheres or with laser doppler imaging. Also, the myocyte necrosis and muscle regeneration in the ischemic gastrocnemius muscle was identical in both PROM-1 deficient mice and their wild-type littermates.

Tumor models

The role of PROM-1 will also be tested in tumor models. The following mouse models are operational and will be used to analyze tumor angiogenesis in vivo: 1) subcutaneous injection of ras-transformed fibroblasts in athymic nude (nu/nu) mice, 2) subcutaneous injection of Lewis lung carcinoma cells in syngenic C57Bl6 hosts, and 3) subcutaneous inoculation of rat C6 glioma cells of athymic nude (nu/nu) mice. Five to twenty million of tumor cells will be inoculated in the mice and tumor growth will be followed up to 30 days. Tumors will be measured with calipers and tumor volumes calculated using the formula [$\pi/6 \times (w1 \times w2 \times w2)$],

where "w1" and "w2" represent the largest and smallest tumor diameter, respectively. Tumor vessel density and size will be determined on tissue sections using immunohistochemistry for visualization of endothelial cells (CD-31), in combination with quantitative morphometry of vascular densities and patterning. If necessary, intratumor flow will be determined using colored microspheres to quantitate flow across the entire tumor.

RAS transformed fibroblasts of PROM-1 deficient and WT mice were injected subcutaneously in athymic nude WT mice. Tumor growth was significantly reduced after inoculation of PROM-1 deficient tumor cells (tumor weight after 14 days: 1.1 ± 0.3 g in PROM-1^{+/+} derived tumors versus 0.5 ± 0.2 g in PROM-1^{-/-} derived tumors; n=7; p< 0.05). Histological analysis of the tumor sections revealed that the vessel density was reduced in the PROM-1 deficient tumors (513.2 ± 48.8 vessels/mm² in PROM-1^{+/+} mice versus 396.3 ± 33.9 vessels/mm² in PROM-1^{-/-} mice; n=7; p= NS). No difference in mean vessel area was observed. However, when WT RAS transformed fibroblasts were injected in PROM-1 deficient and WT nude mice, no difference in tumor weight was seen (tumor weight after 14 days: 0.9 ± 0.1 g in PROM-1^{+/+} hosts versus 1.1 ± 0.3 g in PROM-1^{-/-} hosts; n=7; p< 0.05). Blood vessel analysis is being performed.

Inoculation of LLC tumor cells (20×10^6 cells) in PROM-1 deficient and WT mice (50% B16/50%129) induced tumors after 2 days. Tumor weight was reduced in the PROM-1 deficient hosts during the first days after inoculation but seemed to catch up after 1 week (see table). Vessel growth was analysed in tumors harvested 14 days after inoculation. No differences were found in vessel density or in vessel area. In a second experiment tumors were harvested after 4 days and they are now being analysed.

Table: Weight of LLO tumors

| Trial 1 | WT | | HO | | n | Bonferroni |
|---------|---------|-------|---------|-------|---|------------|
| | Average | SEM | Average | SEM | | |
| Day2 | 0.79 | 0.077 | 0.5 | 0.044 | 5 | |
| Day4 | 0.85 | 0 | 0.55 | 0.037 | 5 | |
| Day6 | 1.02 | 0.051 | 0.867 | 0.058 | 5 | |
| Day8 | 1.31 | 0.085 | 1.128 | 0.086 | 5 | |
| Day10 | 1.75 | 0.11 | 1.71 | 0.11 | 5 | p=0.024 |
| Day12 | 1.9 | 0.14 | 1.89 | 0.16 | 5 | NS |
| Day14 | 2.22 | 0.13 | 2.49 | 0.16 | 5 | NS |

| Trial 2 | WT | | HO | | n | <u>Bonferroni</u> |
|---------|---------|-------|---------|------|---|-------------------|
| | Average | SE | Average | SE | | |
| Day2 | 0.089 | 0.064 | 0.56 | 0.04 | 8 | |
| Day4 | 1.02 | 0.058 | 0.63 | 0.06 | 8 | p=0.0002 |

LPS induced venous thrombosis in footpad

5 To study whether PROM-1 is important in inflammatory processes, a chronic inflammation footpad assay was used. Endotoxin (20µl, E. Coli lipopolysaccharide, 5 and 50 µg/ml) was injected into the right footpad of both PROM-1 deficient and WT mice as described (Carmeliet et al, PAI II). Saline will be injected into the left footpad as a control. After 5 days, mice were sacrificed and both right and left footpad were measured with callipers, excised and fixed in 10 1% paraformaldehyde for 24 hours. Subsequently, footpads were embedded in paraffin and sectioned. Veins will be scored on haematoxylin and eosin stained sections for the presence of thrombi.

15 Five days after injecting 50 µg/ml of endotoxin, a decrease in footpad thickness was observed in the PROM-1 deficient compared to their WT controls.

- To study the role of PROM-1 in the involvement of endothelial progenitor cells (EPCs), murine splenocytes of PROM-1 deficient mice and their wild-type littermates were isolated and subjected to an *in vitro* endothelial progenitor cell

assay (EPC) assay²¹. Splenocytes were isolated by FACS fractionation of murine spleen and plated on fibronectin-coated 24-well plates. After 4 days of culture, cells were stained with Dil-labeled acetyl-LDL and Alexa 488-conjugated isolectin-B4 and examined with a confocal microscope. EPCs are identified as acetyl-LDL and isolectin-B4 double-positive cells. Initial experiments revealed an increased number of EPCs in cultures obtained from wild-type spleens compared to those from AC deficient spleens ($358 \pm 41/\text{mm}^2$ in PROM-1^{+/+} mice versus $179 \pm 19/\text{mm}^2$ in PROM-1^{-/-} mice, $n=3$; $p=0.0171$).

- To investigate the role of PROM-1 in EPC mobilization from bone marrow in conditions of pathological blood vessel formation, EPC assays using cells from mice subjected to the hindlimb ischemia model (see above) will be performed. The first time point will be 7 days post-ligation, since after hindlimb ischemia maximal EPC mobilization was shown at this time point²³.
- RNA of PROM-1 deficient and WT EPCs will be used to analyze expression of VEGF, PlGF, Flk1, Flt1, etc. by RT-PCR.
- In order to study the in vivo role of PROM-1 in the involvement of hematopoietic progenitors or vascular progenitors in blood vessel formation, PROM-1 deficient and wild-type mice will be subjected to wild-type bone marrow transplantations or transplantations of population enriched progenitors. Four weeks after sublethal irradiation and transplantation, mice will be subjected to some of the angiogenesis assays described above. (see corneal micropocket)

All these preliminary data clearly indicate a role of AC 133 in pathological vasculogenesis and/or angiogenesis and implicate the use of inhibitors of PROM-1 in therapeutic strategies to inhibit blood vessel formation in various pathological disorders.

References

1. Risau W. Mechanisms of angiogenesis. *Nature* 1997;386(6626):671-4.
2. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 1997;275(5302):964-7.
3. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, et al. Evidence for circulating bone marrow-derived endothelial cells. *Blood* 1998;92(2):362-7.
4. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nat Med* 1999;5(4):434-8.
5. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. *Circ Res* 1999;85(3):221-8.
6. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. *Embo J* 1999;18(14):3964-72.
7. Bhattacharya V, McSweeney PA, Shi Q, Bruno B, Ishida A, Nash R, et al. Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34(+) bone marrow cells. *Blood* 2000;95(2):581-5.
8. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. *Proc Natl Acad Sci U S A* 2000;97(7):3422-7.
9. Schatteman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. *J Clin Invest* 2000;106(4):571-8.
10. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. *Circulation* 2001;103(5):634-7.
11. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat Med* 2001;7(4):430-6.

12. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ Res* 2001;89(1):E1-7.
13. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. *Circ Res* 2001;88(2):167-74.
14. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. *Blood* 1997;90(12):5013-21.
15. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. *Blood* 1997;90(12):5002-12.
16. de Wynter EA, Buck D, Hart C, Heywood R, Coutinho LH, Clayton A, et al. CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. *Stem Cells* 1998;16(6):387-96.
17. Buhring HJ, Seiffert M, Bock TA, Scheduling S, Thiel A, Scheffold A, et al. Expression of novel surface antigens on early hematopoietic cells. *Ann N Y Acad Sci* 1999;872:25-38; discussion 38-9.
18. Horn PA, Tesch H, Staib P, Kube D, Diehl V, Voliotis D. Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells. *Blood* 1999;93(4):1435-7.
19. Kratz-Albers K, Zuhlsdorf M, Leo R, Berdel WL, Buchner T, Serve H. Expression of a AC133, a novel stem cell marker, on human leukemic blasts lacking CD34-antigen and on a human CD34+ leukemic line:MUTZ-2. *Blood* 1998;92(11):4485-7.
20. Buhring HJ, Seiffert M, Marxer A, Weiss B, Faul C, Kanz L, et al. AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors. *Blood* 1999;94(2):832-3.
21. Corbeil D, Roper K, Hannah MJ, Hellwig A, Huttner WB. Selective localization of the polytopic membrane protein prominin in microvilli of epithelial cells - a combination of apical sorting and retention in plasma membrane protrusions. *J Cell Sci* 1999;112(Pt 7):1023-33.

22. Gehling UM, Ergun S, Schumacher U, Wagener C, Panter R, Otte M, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. *Blood* 2000;95(10):3106-12.
23. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. *Blood* 2000;95(3):952-8.
24. Quirici N, Soligo D, Caneva L, Servida F, Bossolasco P, Deliliers GL. Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. *Br J Haematol* 2001;115(1):186-94.
25. Corbeil D, Roper K, Weigmann A, Huttner WB. AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? *Blood* 1998;91(7):2625-6.
26. Miraglia S, Godfrey W, Buck D. A response to AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? *Blood* 1998;91(11):4390-1.
27. Wilson R, Ainscough R, Anderson K, Baynes C, Berks M, Bonfield J, et al. 2.2 Mb of contiguous nucleotide sequence from chromosome III of *C. elegans*. *Nature* 1994;368(6466):32-8.
28. Weigmann A, Corbeil D, Hellwig A, Huttner WB. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. *Proc Natl Acad Sci U S A* 1997;94(23):12425-30.
29. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, et al. Oxygen-induced retinopathy in the mouse. *Invest Ophthalmol Vis Sci* 1994;35(1):101-11.
30. Wesolowski E, Smith LE. Effect of light on oxygen-induced retinopathy in the mouse. *Invest Ophthalmol Vis Sci* 1994;35(1):112-9.
31. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. *Proc Natl Acad Sci U S A* 1995;92(3):905-9.

1. Miraglia S, Godfrey L, Yin AH, Atkins K, Warnke R, Holden KR, Bray RA, Waller EK, Buck DW. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. *Blood* 1997;90(12):5013-21.
2. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. PROM-1, a novel marker for human hematopoietic stem and progenitor cells. *Blood* 1997;90(12):5002-12.
3. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, Schuch G, Schafhausen P, Mende T, Kilic N and others. In vitro differentiation of endothelial cells from PROM-1-positive progenitor cells. *Blood* 2000;95(10):3106-12.
4. Boyer M, Townsend LE, Vogel LM, Falk J, Reitz-Vick D, Trevor KT, Villalba M, Bendick PJ, Glover JL. Isolation of endothelial cells and their progenitor cells from human peripheral blood. *J Vasc Surg* 2000;31(1 Pt 1):181-9.
5. Quirici N, Soligo D, Caneva L, Servida F, Bossolasco P, Deliliers GL. Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. *Br J Haematol* 2001;115(1):186-94.
6. Buhring HJ, Seiffert M, Bock TA, Scheduling S, Thiel A, Scheffold A, Kanz L, Brugger W. Expression of novel surface antigens on early hematopoietic cells. *Ann N Y Acad Sci* 1999;872:25-38; discussion 38-9.
7. Horn PA, Tesch H, Staib P, Kube D, Diehl V, Voliotis D. Expression of PROM-1, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells. *Blood* 1999;93(4):1435-7.
8. Kratz-Albers K, Zuhlsdorf M, Leo R, Berdel WL, Buchner T, Serve H. Expression of a PROM-1, a novel stem cell marker, on human leukemic blasts lacking CD34-antigen and on a human CD34+ leukemic line:MUTZ-2. *Blood* 1998;92(11):4485-7.
9. Buhring HJ, Seiffert M, Marxer A, Weiss B, Faul C, Kanz L, Brugger W. PROM-1 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors. *Blood* 1999;94(2):832-3.
10. Corbeil D, Roper K, Hannah MJ, Hellwig A, Huttner WB. Selective localization of the polytopic membrane protein prominin in microvilli of epithelial cells - a combination of apical sorting and retention in plasma membrane protrusions. *J Cell Sci* 1999;112(Pt 7):1023-33.

11. Peichev M, Naiyer AS, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA and others. Expression of VEGFR-2 and PROM-1 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. *Blood* 2000;95(3):952-8.
- 5 12. Rafii S. Circulating endothelial precursors: mystery, reality, and promise. *J Clin Invest* 2000;105(1):17-9.
13. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL. Direct isolation of human central nervous system stem cells. *Proc Natl Acad Sci U S A* 2000;97(26):14720-5.
- 10 14. Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck DW, Huttner WB. The human PROM-1 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. *J Biol Chem* 2000;275(8):5512-20.
- 15 15. Yu Y, Flint A, Dvorin EL, Bischoff J. PROM-1-2, a Novel Isoform of Human PROM-1 Stem Cell Antigen. *J Biol Chem* 2002;277(23):20711-6.
- 16 16. Maw MA, Corbeil D, Koch J, Hellwig A, Wilson-Wheeler JC, Bridges RJ, Kumaramanickavel G, John S, Nancarrow D, Roper K and others. A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. *Hum Mol Genet* 2000;9(1):27-34.
- 20 17. Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. *Traffic* 2001;2(2):82-91.
18. Corbeil D, Roper K, Weigmann A, Huttner WB. PROM-1 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? *Blood* 1998;91(7):2625-6.
- 25 19. Miraglia S, Godfrey W, Buck D. A response to PROM-1 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? *Blood* 1998;91(11):4390-1.
20. Risau W. Mechanisms of angiogenesis. *Nature* 1997;386(6626):671-4.
- 30 21. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 1997;275(5302):964-7.

22. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita T, Kothari S, Mohle R, Sauvage LR and others. Evidence for circulating bone marrow-derived endothelial cells. *Blood* 1998;92(2):362-7.
23. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Wagner M, Isner JM, Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nat Med* 1999;5(4):434-8.
24. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Wagner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. *Circ Res* 1999;85(3):221-8.
25. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. *Embo J* 1999;18(14):3964-72.
26. Bhattacharya V, McSweeney PA, Shi Q, Bruno B, Ishida A, Nash R, Storb RF, Sauvage LR, Hammond WP, Wu MH. Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34(+) bone marrow cells. *Blood* 2000;95(2):581-5.
27. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. *Proc Natl Acad Sci U S A* 2000;97(7):3422-7.
28. Schatteman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. *J Clin Invest* 2000;106(4):571-8.
29. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, Silver M, Ma H, Kearney M, Isner JM and others. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. *Circulation* 2001;103(5):634-7.
30. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat Med* 2001;7(4):430-6.

31. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ Res* 2001;89(1):E1-7.
- 5 32. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel H, Rafii S. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)PROM-1(+) endothelial precursor cells. *Circ Res* 2001;88(2):167-74.
33. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA. Oxygen-induced retinopathy in the mouse. *Invest Ophthalmol Vis Sci* 1994;35(1):101-11.
- 10 34. Wesolowski E, Smith LE. Effect of light on oxygen-induced retinopathy in the mouse. *Invest Ophthalmol Vis Sci* 1994;35(1):112-9.
35. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. *Invest Ophthalmol Vis Sci* 1996;37(8):1625-32.
- 15 36. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, Isner JM. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF- induced postnatal neovascularization. *Circ Res* 1998;83(3):233-40.
- 20 37. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. *J Biol Chem* 1995;270(21):12607-13.
- 25 38. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernelle V, De Mol M, Wu Y, Bono F, Devy L, Beck H and others. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. *Nat Med* 2001;7(5):575-83.
- 30 39. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. *Lab Invest* 1992;67(4):519-28.
40. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A and others. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture

but impairs therapeutic angiogenesis and causes cardiac failure. *Nat Med* 1999;5(10):1135-42.

41. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B and others. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. *Nat Med* 2002;8(8):831-40.
42. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. *Genes Dev* 1999;13(9):1055-66.
43. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. *Nat Med* 2000;6(4):389-95.
44. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K and others. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. *Am J Pathol* 1999;154(2):385-94.
45. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. *Cell* 1999;98(6):769-78.
46. Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. *Trends Immunol* 2001;22(6):317-21.
47. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG and others. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. *Embo J* 2001;20(6):1223-31.
48. Sleeman JP, Krishnan J, Kirkin V, Baumann P. Markers for the lymphatic endothelium: in search of the holy grail? *Microsc Res Tech* 2001;55(2):61-9.
49. Witte MH, Bernas MJ, Martin CP, Witte CL. Lymphangiogenesis and lymphangiodysplasia: from molecular to clinical lymphology. *Microsc Res Tech* 2001;55(2):122-45.
50. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. *Cancer Res* 2001;61(5):1786-90.

51. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG and others. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. *Embo J* 2001;20(4):672-82.
- 5 52. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. *Nat Med* 2001;7(2):192-8.
53. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. *Nat Med* 2001;7(2):186-91.
- 10 54. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. *Cancer Cell* 2002;1(3):219-27.
55. Oliver G, Detmar M. The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. *Genes Dev* 2002;16(7):773-83.
- 15 56. Schneider M, Othman-Hassan K, Christ B, Wilting J. Lymphangioblasts in the avian wing bud. *Dev Dyn* 1999;216(4-5):311-9.
57. Kubo H, Cao R, Brakenhielm E, Makinen T, Cao Y, Alitalo K. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. *Proc Natl Acad Sci U S A* 2002;99(13):8868-73.
- 20 58. Folkman J. A mechanism for regulation of lymphangiogenesis independent of angiogenesis. Bethesda; 2002.
59. Baldwin M, Catimel B, Nice EC, Roufail S, Hall NE, Stenvers KL, Karkkainen MJ, Alitalo K, Stacker SA, M.G. A. The Specificity of Receptor Binding by Vascular Endothelial Growth Factor-D Is Different in Mouse and Man. *J. Biol. Chem.* 2001;276(22):19166-19171.
- 25 60. Boardman KC, Swartz MA. Lymphangiogenesis in a mouse tail model. 2001. p 671-672.
- 30 61. Ikomi F, Ohhashi T. Immunohistochemical expression of VEGF receptors on new vascularization of collecting lymphatics in mice. In: Editore M, editor; 2001; Sidney, Australia. p 387-390.

62. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. *Science* 1992;255(5052):1707-10.
63. Gage FH. Mammalian neural stem cells. *Science* 2000;287(5457):1433-8.
- 5 64. Yamamoto S, Yamamoto N, Kitamura T, Nakamura K, Nakafuku M. Proliferation of parenchymal neural progenitors in response to injury in the adult rat spinal cord. *Exp Neurol* 2001;172(1):115-27.
65. Cao Q, Benton RL, Whittemore SR. Stem cell repair of central nervous system injury. *J Neurosci Res* 2002;68(5):501-10.
- 10 66. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. *Nat Med* 2002;8(9):963-70.
67. Kempermann G, Kuhn HG, Gage FH. Genetic influence on neurogenesis in the dentate gyrus of adult mice. *Proc Natl Acad Sci U S A* 1997;94(19):10409-14.
- 15 68. Kuhn HG, Palmer TD, Fuchs E. Adult neurogenesis: a compensatory mechanism for neuronal damage. *Eur Arch Psychiatry Clin Neurosci* 2001;251(4):152-8.
69. Gritti A, Parati EA, Cova L, Frolichsthal P, Galli R, Wanke E, Faravelli L, Morassutti DJ, Roisen F, Nickel DD and others. Multipotential stem cells from the adult mouse brain proliferate and self-renew in response to basic fibroblast growth factor. *J Neurosci* 1996;16(3):1091-100.
- 20 70. Takagi Y, Mitsui A, Nishiyama A, Nozaki K, Sono H, Gon Y, Hashimoto N, Yodoi J. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. *Proc Natl Acad Sci U S A* 1999;96(7):4131-6.
- 25 71. Tamaki S, Eckert K, He D, Sutton R, Doshe M, Jain G, Tushinski R, Reitsma M, Harris B, Tsukamoto A and others. Engraftment of sorted/expanded human central nervous system stem cells from fetal brain. *J Neurosci Res* 2002;69(6):976-86.
72. Wu S, Suzuki Y, Kitada M, Kataoka K, Kitaura M, Chou H, Nishimura Y, Ide C. New method for transplantation of neurosphere cells into injured spinal cord through cerebrospinal fluid in rat. *Neurosci Lett* 2002;318(2):81-4.
- 30 73. Lang-Lazdunski L, Matsushita K, Hirt L, Waeber C, Vonsattel JP, Moskowitz MA, Dietrich WD. Spinal cord ischemia. Development of a model in the mouse. *Stroke* 2000;31(1):208-13.

74. Rapalino O, Lazarov-Spiegler O, Agranov E, Velan GJ, Toles E, Fraidakis M, Solomon A, Gepstein R, Katz A, Belkin M and others. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med 1998;4(7):814-21.

Claims


- 5 1. Use of a molecule which comprises a region specifically binding to AC133 or nucleic acids encoding AC133, for the manufacture of a medicament to treat pathological angiogenesis.
- 10 2. Use according to claim 1 wherein said molecule is chosen from the list comprising an antibody or any fragment thereof binding to AC133, a small molecule specifically binding to AC133 or nucleic acids encoding AC133, a ribozyme against nucleic acids encoding AC133, and anti-sense nucleic acids hybridising with nucleic acids encoding AC133.
- 15 3. A method to identify molecules that comprise a region that specifically binds to AC133 comprising:
- exposing AC133 or nucleic acids encoding AC133 to at least one molecule whose ability to suppress or prevent pathological angiogenesis is sought to be determined,
 - determining binding or hybridising of said molecule(s) to AC133 or nucleic acids encoding AC133, and
 - 20 - monitoring said pathological angiogenesis when administering said molecules as a medicament.
- 25
- 30

Abstract

The invention relates to the field of pathological angiogenesis. In particular the invention relates to the use of molecules binding to AC133 that can be used for the manufacture of a medicament to prevent angiogenesis.

5

Fig. 1: Healing of wounds in AC133 deficient mice and wild-type littermates



These data clearly indicate a role of AC 133 in pathological vasculogenesis and/or angiogenesis and implicate the use of inhibitors of AC133 in therapeutic strategies to inhibit blood vessel formation in various pathological disorders.

SEQUENCE LISTING

<110> VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW

<120> A NOVEL TARGET TO INHIBIT ANGIOGENESIS

<130> PCA/AC133/144

<160> 2

<170> PatentIn version 3.1

<210> 1

<211> 3794

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (38) .. (2635)

<223>

<400> 1

ccaagttcta cctcatgttt ggaggatctt gctagct atg gcc ctc gta ctc ggc
55

Met Ala Leu Val Leu Gly
1 5

tcc ctg ttg ctg ctg ggg ctg tgc ggg aac tcc ttt tca gga ggg cag
103

Ser Leu Leu Leu Leu Gly Leu Cys Gly Asn Ser Phe Ser Gly Gly Gln
10 15 20

cct tca tcc aca gat gct cct aag gct tgg aat tat gaa ttg cct gca
151

Pro Ser Ser Thr Asp Ala Pro Lys Ala Trp Asn Tyr Glu Leu Pro Ala
25 30 35

aca aat tat gag acc caa gac tcc cat aaa gct gga ccc att ggc att
199

Thr Asn Tyr Glu Thr Gln Asp Ser His Lys Ala Gly Pro Ile Gly Ile
40 45 50

ctc ttt gaa cta gtg cat atc ttt ctc tat gtg gta cag ccg cgt gat
247

Leu Phe Glu Leu Val His Ile Phe Leu Tyr Val Val Gln Pro Arg Asp
55 60 65 70

ttc cca gaa gat act ttg aga aaa ttc tta cag aag gca tat gaa tcc
295

Phe Pro Glu Asp Thr Leu Arg Lys Phe Leu Gln Lys Ala Tyr Glu Ser
75 80 85

aaa att gat tat gac aag cca gaa act gta atc tta ggt cta aag att
343

Lys Ile Asp Tyr Asp Lys Pro Glu Thr Val Ile Leu Gly Leu Lys Ile
90 95 100

gtc tac tat gaa gca ggg att att cta tgc tgt gtc ctg ggg ctg ctg
391

Val Tyr Tyr Glu Ala Gly Ile Ile Leu Cys Cys Val Leu Gly Leu Leu
105 110 115

ttt att att ctg atg cct ctg gtg ggg tat ttc ttt tgt atg tgt cgt
439

Phe Ile Ile Leu Met Pro Leu Val Gly Tyr Phe Phe Cys Met Cys Arg
120 125 130

tgc tgt aac aaa tgt ggt gga gaa atg cac cag cga cag aag gaa aat
487

Cys Cys Asn Lys Cys Gly Gly Glu Met His Gln Arg Gln Lys Glu Asn
135 140 145 150

ggg ccc ttc ctg agg aaa tgc ttt gca atc tcc ctg ttg gtg att tgt
535

Gly Pro Phe Leu Arg Lys Cys Phe Ala Ile Ser Leu Leu Val Ile Cys
155 160 165

ata ata ata agc att ggc atc ttc tat ggt ttt gtg gca aat cac cag
583

Ile Ile Ile Ser Ile Gly Ile Phe Tyr Gly Phe Val Ala Asn His Gln
170 175 180

gta aga acc cgg atc aaa agg agt cgg aaa ctg gca gat agc aat ttc
631

Val Arg Thr Arg Ile Lys Arg Ser Arg Lys Leu Ala Asp Ser Asn Phe
185 190 195

aag gac ttg cga act ctc ttg aat gaa act cca gag caa atc aaa tat
679

Lys Asp Leu Arg Thr Leu Leu Asn Glu Thr Pro Glu Gln Ile Lys Tyr
 200 205 210
 ata ttg gcc cag tac aac act acc aag gac aag gcg ttc aca gat ctg
 727
 Ile Leu Ala Gln Tyr Asn Thr Thr Lys Asp Lys Ala Phe Thr Asp Leu
 215 220 225 230
 aac agt atc aat tca gtg cta gga ggc gga att ctt gac cga ctg aga
 775
 Asn Ser Ile Asn Ser Val Leu Gly Gly Gly Ile Leu Asp Arg Leu Arg
 235 240 245
 ccc aac atc atc cct gtt ctt gat gag att aag tcc atg gca aca gcg
 823
 Pro Asn Ile Ile Pro Val Leu Asp Glu Ile Lys Ser Met Ala Thr Ala
 250 255 260
 atc aag gag acc aaa gag gcg ttg gag aac atg aac agc acc ttg aag
 871
 Ile Lys Glu Thr Lys Glu Ala Leu Glu Asn Met Asn Ser Thr Leu Lys
 265 270 275
 agc ttg cac caa caa agt aca cag ctt agc agc agt ctg acc agc gtg
 919
 Ser Leu His Gln Gln Ser Thr Gln Leu Ser Ser Ser Leu Thr Ser Val
 280 285 290
 aaa act agc ctg cgg tca tct ctc aat gac cct ctg tgc ttg gtg cat
 967
 Lys Thr Ser Leu Arg Ser Ser Leu Asn Asp Pro Leu Cys Leu Val His
 295 300 305 310
 cca tca agt gaa acc tgc aac agc atc aga ttg tct cta agc cag ctg
 1015
 Pro Ser Ser Glu Thr Cys Asn Ser Ile Arg Leu Ser Leu Ser Gln Leu
 315 320 325
 aat agc aac cct gaa ctg agg cag ctt cca ccc gtg gat gca gaa ctt
 1063
 Asn Ser Asn Pro Glu Leu Arg Gln Leu Pro Pro Val Asp Ala Glu Leu
 330 335 340
 gac aac gtt aat aac gtt ctt agg aca gat ttg gat ggc ctg gtc caa
 1111
 Asp Asn Val Asn Asn Val Leu Arg Thr Asp Leu Asp Gly Leu Val Gln
 345 350 355
 cag ggc tat caa tcc ctt aat gat ata cct gac aga gta caa cgc caa
 1159
 Gln Gly Tyr Gln Ser Leu Asn Asp Ile Pro Asp Arg Val Gln Arg Gln
 360 365 370

acc acg act gtc gta gca ggt atc aaa agg gtc ttg aat tcc att ggt
1207

Thr Thr Thr Val Val Ala Gly Ile Lys Arg Val Leu Asn Ser Ile Gly
375 380 385 390

tca gat atc gac aat gta act cag cgt ctt cct att cag gat ata ctc
1255

Ser Asp Ile Asp Asn Val Thr Gln Arg Leu Pro Ile Gln Asp Ile Leu
395 400 405

tca gca ttc tct gtt tat gtt aat aac act gaa agt tac atc cac aga
1303

Ser Ala Phe Ser Val Tyr Val Asn Asn Thr Glu Ser Tyr Ile His Arg
410 415 420

aat tta cct aca ttg gaa gag tat gat tca tac tgg tgg ctg ggt ggc
1351

Asn Leu Pro Thr Leu Glu Glu Tyr Asp Ser Tyr Trp Trp Leu Gly Gly
425 430 435

ctg gtc atc tgc tct ctg ctg acc ctc atc gtg att ttt tac tac ctg
1399

Leu Val Ile Cys Ser Leu Leu Thr Leu Ile Val Ile Phe Tyr Tyr Leu
440 445 450

ggc tta ctg tgt ggc gtg tgc ggc tat gac agg cat gcc acc ccg acc
1447

Gly Leu Leu Cys Gly Val Cys Gly Tyr Asp Arg His Ala Thr Pro Thr
455 460 465 470

acc cga ggc tgt gtc tcc aac acc gga ggc gtc ttc ctc atg gtt gga
1495

Thr Arg Gly Cys Val Ser Asn Thr Gly Gly Val Phe Leu Met Val Gly
475 480 485

gtt gga tta agt ttc ctc ttt tgc tgg ata ttg atg atc att gtg gtt
1543

Val Gly Leu Ser Phe Leu Phe Cys Trp Ile Leu Met Ile Ile Val Val
490 495 500

ctt acc ttt gtc ttt ggt gca aat gtg gaa aaa ctg atc tgt gaa cct
1591

Leu Thr Phe Val Phe Gly Ala Asn Val Glu Lys Leu Ile Cys Glu Pro
505 510 515

tac acg agc aag gaa tta ttc cgg gtt ttg gat aca ccc tac tta cta
1639

Tyr Thr Ser Lys Glu Leu Phe Arg Val Leu Asp Thr Pro Tyr Leu Leu
520 525 530

aat gaa gac tgg gaa tac tat ctc tct ggg aag cta ttt aat aaa tca
1687

Asn Glu Asp Trp Glu Tyr Tyr Leu Ser Gly Lys Leu Phe Asn Lys Ser
535 540 545 550

aaa atg aag ctc act ttt gaa caa gtt tac agt gac tgc aaa aaa aat
1735

Lys Met Lys Leu Thr Phe Glu Gln Val Tyr Ser Asp Cys Lys Lys Asn
555 560 565

aga ggc act tac ggc act ctt cac ctg cag aac agc ttc aat atc agt
1783

Arg Gly Thr Tyr Gly Thr Leu His Leu Gln Asn Ser Phe Asn Ile Ser
570 575 580

gaa cat ctc aac att aat gag cat act gga agc ata agc agt gaa ttg
1831

Glu His Leu Asn Ile Asn Glu His Thr Gly Ser Ile Ser Ser Glu Leu
585 590 595

gaa agt ctg aag gta aat ctt aat atc ttt ctg ttg ggt gca gca gga
1879

Glu Ser Leu Lys Val Asn Leu Asn Ile Phe Leu Leu Gly Ala Ala Gly
600 605 610

aga aaa aac ctt cag gat ttt gct gct tgt gga ata gac aga atg aat
1927

Arg Lys Asn Leu Gln Asp Phe Ala Ala Cys Gly Ile Asp Arg Met Asn
615 620 625 630

tat gac agc tac ttg gct cag act ggt aaa tcc ccc gca gga gtg aat
1975

Tyr Asp Ser Tyr Leu Ala Gln Thr Gly Lys Ser Pro Ala Gly Val Asn
635 640 645

ctt tta tca ttt gca tat gat cta gaa gca aaa gca aac agt ttg ccc
2023

Leu Leu Ser Phe Ala Tyr Asp Leu Glu Ala Lys Ala Asn Ser Leu Pro
650 655 660

cca gga aat ttg agg aac tcc ctg aaa aga gat gca caa act att aaa
2071

Pro Gly Asn Leu Arg Asn Ser Leu Lys Arg Asp Ala Gln Thr Ile Lys
665 670 675

aca att cac cag caa cga gtc ctt cct ata gaa caa tca ctg agc act
2119

Thr Ile His Gln Gln Arg Val Leu Pro Ile Glu Gln Ser Leu Ser Thr
680 685 690

cta tac caa agc gtc aag ata ctt caa cgc aca ggg aat gga ttg ttg
2167

Leu Tyr Gln Ser Val Lys Ile Leu Gln Arg Thr Gly Asn Gly Leu Leu
 695 700 705 710
 gag aga gta act agg att cta gct tct ctg gat ttt gct cag aac ttc
 2215
 Glu Arg Val Thr Arg Ile Leu Ala Ser Leu Asp Phe Ala Gln Asn Phe
 715 720 725
 atc aca aac aat act tcc tct gtt att att gag gaa act aag aag tat
 2263
 Ile Thr Asn Asn Thr Ser Ser Val Ile Ile Glu Glu Thr Lys Lys Tyr
 730 735 740
 ggg aga aca ata ata gga tat ttt gaa cat tat ctg cag tgg atc gag
 2311
 Gly Arg Thr Ile Ile Gly Tyr Phe Glu His Tyr Leu Gln Trp Ile Glu
 745 750 755
 ttc tct atc agt gag aaa gtg gca tcg tgc aaa cct gtg gcc acc gct
 2359
 Phe Ser Ile Ser Glu Lys Val Ala Ser Cys Lys Pro Val Ala Thr Ala
 760 765 770
 cta gat act gct gtt gat gtc ttt ctg tgt agc tac att atc gac ccc
 2407
 Leu Asp Thr Ala Val Asp Val Phe Leu Cys Ser Tyr Ile Ile Asp Pro
 775 780 785 790
 ttg aat ttg ttt tgg ttt ggc ata gga aaa gct act gta ttt tta ctt
 2455
 Leu Asn Leu Phe Trp Phe Gly Ile Gly Lys Ala Thr Val Phe Leu Leu
 795 800 805
 ccg gct cta att ttt gcg gta aaa ctg gct aag tac tat cgt cga atg
 2503
 Pro Ala Leu Ile Phe Ala Val Lys Leu Ala Lys Tyr Tyr Arg Arg Met
 810 815 820
 gat tcg gag gac gtg tac gat gat gtt gaa act ata ccc atg aaa aat
 2551
 Asp Ser Glu Asp Val Tyr Asp Asp Val Glu Thr Ile Pro Met Lys Asn
 825 830 835
 atg gaa aat ggt aat aat ggt tat cat aaa gat cat gta tat ggt att
 2599
 Met Glu Asn Gly Asn Asn Gly Tyr His Lys Asp His Val Tyr Gly Ile
 840 845 850
 cac aat cct gtt atg aca agc cca tca caa cat tga tagctgatgt
 2645
 His Asn Pro Val Met Thr Ser Pro Ser Gln His
 855 860 865

tgaaactgct tgagcatcag gataactcaaa gtggaaagga tcacagattt ttggtagttt
2705

ctgggtctac aaggactttc caaatccagg agcaacgcca gtggcaacgt agtgactcag
2765

gcgggcacca aggcaacggc accattggtc tctgggtagt gctttaagaa tgaacacaat
2825

cacgttatag tccatgggcc atcactattc aaggatgact ccctcccttc ctgtctattt
2885

ttgtttttta cttttttaca ctgagtttct atttagacac tacaacatat ggggtgtttg
2945

ttccattgg atgcatttct atcaaaactc tatcaaagt gatggctaga ttctaacata
3005

ttgccatgtg tggagtgtgc tgaacacaca ccagtttaca ggaaagatgc attttgtgta
3065

cagtaaacgg tgtatatacc ttttgttacc acagagtttt ttaaacaaat gagtattata
3125

ggactttctt ctaaagagc taaataagtc accattgact tcttgggtgct gttgaaaata
3185

atccattttc actaaaagtg tgtgaaacct acagcatatt cttcacgcag agattttcat
3245

ctattatact ttatcaaaga ttggccatgt tccacttga aatggcatgc aaaagccatc
3305

atagagaaac ctgcgtaact ccatctgaca aattcaaaag agagagagag atcttgagag
3365

agaaatgctg ttcggtcaaa agtggagttg ttttaacaga tgccaattac ggtgtacagt
3425

ttaacagagt tttctgttgc attaggataa acattaattg gagtgcagct aacatgagta
3485

tcacagact agtatcaagt gttctaaaat gaaatatgag aagatcctgt cacaattctt
3545

agatctggtg tccagcatgg atgaaacctt tgagtttggc ccctaaattt gcatgaaagc
3605

acaaggtaaa tattcatttg cttcaggagt ttcattgttg atctgtcatt atcaaaagtg
3665

atcagcaatg aagaactggt cggacaaaat ttaacgttga tgtaatggaa ttccagatgt
3725

aggcattccc cccaggtcctt ttcattgtgca gattgcagtt ctgattcatt tgaataaaaa
3785

ggaacttgg
3794

<210> 2

<211> 865

<212> PRT

<213> Homo sapiens

<400> 2

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Leu | Val | Leu | Gly | Ser | Leu | Leu | Leu | Leu | Gly | Leu | Cys | Gly | Asn |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Phe | Ser | Gly | Gly | Gln | Pro | Ser | Ser | Thr | Asp | Ala | Pro | Lys | Ala | Trp |
| | | | 20 | | | | | 25 | | | | | 30 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Tyr | Glu | Leu | Pro | Ala | Thr | Asn | Tyr | Glu | Thr | Gln | Asp | Ser | His | Lys |
| | 35 | | | | | | 40 | | | | | 45 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Gly | Pro | Ile | Gly | Ile | Leu | Phe | Glu | Leu | Val | His | Ile | Phe | Leu | Tyr |
| | 50 | | | | | 55 | | | | | 60 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Val | Gln | Pro | Arg | Asp | Phe | Pro | Glu | Asp | Thr | Leu | Arg | Lys | Phe | Leu |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Lys | Ala | Tyr | Glu | Ser | Lys | Ile | Asp | Tyr | Asp | Lys | Pro | Glu | Thr | Val |
| | | | | 85 | | | | | 90 | | | | | 95 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Leu | Gly | Leu | Lys | Ile | Val | Tyr | Tyr | Glu | Ala | Gly | Ile | Ile | Leu | Cys |
| | | | 100 | | | | | | 105 | | | | | 110 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Val | Leu | Gly | Leu | Leu | Phe | Ile | Ile | Leu | Met | Pro | Leu | Val | Gly | Tyr |
| | | 115 | | | | | | | 120 | | | | 125 | | |

| | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|
| Phe | Phe | Cys | Met | Cys | Arg | Cys | Cys | Asn | Lys | Cys | Gly | Gly | Glu | Met | His | | |
| 130 | | | | | | 135 | | | | | 140 | | | | | | |
| Gln | Arg | Gln | Lys | Glu | Asn | Gly | Pro | Phe | Leu | Arg | Lys | Cys | Phe | Ala | Ile | | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | | |
| Ser | Leu | Leu | Val | Ile | Cys | Ile | Ile | Ile | Ser | Ile | Gly | Ile | Phe | Tyr | Gly | | |
| | | | | 165 | | | | | 170 | | | | | 175 | | | |
| Phe | Val | Ala | Asn | His | Gln | Val | Arg | Thr | Arg | Ile | Lys | Arg | Ser | Arg | Lys | | |
| | | | 180 | | | | | 185 | | | | | 190 | | | | |
| Leu | Ala | Asp | Ser | Asn | Phe | Lys | Asp | Leu | Arg | Thr | Leu | Leu | Asn | Glu | Thr | | |
| | | 195 | | | | | 200 | | | | | 205 | | | | | |
| Pro | Glu | Gln | Ile | Lys | Tyr | Ile | Leu | Ala | Gln | Tyr | Asn | Thr | Thr | Lys | Asp | | |
| | 210 | | | | | 215 | | | | | 220 | | | | | | |
| Lys | Ala | Phe | Thr | Asp | Leu | Asn | Ser | Ile | Asn | Ser | Val | Leu | Gly | Gly | Gly | | |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 | | |
| Ile | Leu | Asp | Arg | Leu | Arg | Pro | Asn | Ile | Ile | Pro | Val | Leu | Asp | Glu | Ile | | |
| | | | | 245 | | | | | 250 | | | | | 255 | | | |
| Lys | Ser | Met | Ala | Thr | Ala | Ile | Lys | Glu | Thr | Lys | Glu | Ala | Leu | Glu | Asn | | |
| | | | 260 | | | | | 265 | | | | | 270 | | | | |
| Met | Asn | Ser | Thr | Leu | Lys | Ser | Leu | His | Gln | Gln | Ser | Thr | Gln | Leu | Ser | | |
| | | 275 | | | | | 280 | | | | | 285 | | | | | |
| Ser | Ser | Leu | Thr | Ser | Val | Lys | Thr | Ser | Leu | Arg | Ser | Ser | Leu | Asn | Asp | | |
| | 290 | | | | | 295 | | | | | 300 | | | | | | |
| Pro | Leu | Cys | Leu | Val | His | Pro | Ser | Ser | Glu | Thr | Cys | Asn | Ser | Ile | Arg | | |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 | | |
| Leu | Ser | Leu | Ser | Gln | Leu | Asn | Ser | Asn | Pro | Glu | Leu | Arg | Gln | Leu | Pro | | |
| | | | | 325 | | | | | 330 | | | | | 335 | | | |

Pro Val Asp Ala Glu Leu Asp Asn Val Asn Asn Val Leu Arg Thr Asp
 340 345 350

Leu Asp Gly Leu Val Gln Gln Gly Tyr Gln Ser Leu Asn Asp Ile Pro
 355 360 365

Asp Arg Val Gln Arg Gln Thr Thr Thr Val Val Ala Gly Ile Lys Arg
 370 375 380

Val Leu Asn Ser Ile Gly Ser Asp Ile Asp Asn Val Thr Gln Arg Leu
 385 390 395 400

Pro Ile Gln Asp Ile Leu Ser Ala Phe Ser Val Tyr Val Asn Asn Thr
 405 410 415

Glu Ser Tyr Ile His Arg Asn Leu Pro Thr Leu Glu Glu Tyr Asp Ser
 420 425 430

Tyr Trp Trp Leu Gly Gly Leu Val Ile Cys Ser Leu Leu Thr Leu Ile
 435 440 445

Val Ile Phe Tyr Tyr Leu Gly Leu Leu Cys Gly Val Cys Gly Tyr Asp
 450 455 460

Arg His Ala Thr Pro Thr Thr Arg Gly Cys Val Ser Asn Thr Gly Gly
 465 470 475 480

Val Phe Leu Met Val Gly Val Gly Leu Ser Phe Leu Phe Cys Trp Ile
 485 490 495

Leu Met Ile Ile Val Val Leu Thr Phe Val Phe Gly Ala Asn Val Glu
 500 505 510

Lys Leu Ile Cys Glu Pro Tyr Thr Ser Lys Glu Leu Phe Arg Val Leu
 515 520 525

Asp Thr Pro Tyr Leu Leu Asn Glu Asp Trp Glu Tyr Tyr Leu Ser Gly
 530 535 540

Lys Leu Phe Asn Lys Ser Lys Met Lys Leu Thr Phe Glu Gln Val Tyr
545 550 555 560

Ser Asp Cys Lys Lys Asn Arg Gly Thr Tyr Gly Thr Leu His Leu Gln
565 570 575

Asn Ser Phe Asn Ile Ser Glu His Leu Asn Ile Asn Glu His Thr Gly
580 585 590

Ser Ile Ser Ser Glu Leu Glu Ser Leu Lys Val Asn Leu Asn Ile Phe
595 600 605

Leu Leu Gly Ala Ala Gly Arg Lys Asn Leu Gln Asp Phe Ala Ala Cys
610 615 620

Gly Ile Asp Arg Met Asn Tyr Asp Ser Tyr Leu Ala Gln Thr Gly Lys
625 630 635 640

Ser Pro Ala Gly Val Asn Leu Leu Ser Phe Ala Tyr Asp Leu Glu Ala
645 650 655

Lys Ala Asn Ser Leu Pro Pro Gly Asn Leu Arg Asn Ser Leu Lys Arg
660 665 670

Asp Ala Gln Thr Ile Lys Thr Ile His Gln Gln Arg Val Leu Pro Ile
675 680 685

Glu Gln Ser Leu Ser Thr Leu Tyr Gln Ser Val Lys Ile Leu Gln Arg
690 695 700

Thr Gly Asn Gly Leu Leu Glu Arg Val Thr Arg Ile Leu Ala Ser Leu
705 710 715 720

Asp Phe Ala Gln Asn Phe Ile Thr Asn Asn Thr Ser Ser Val Ile Ile
725 730 735

Glu Glu Thr Lys Lys Tyr Gly Arg Thr Ile Ile Gly Tyr Phe Glu His
740 745 750

Tyr Leu Gln Trp Ile Glu Phe Ser Ile Ser Glu Lys Val Ala Ser Cys
755 760 765

Lys Pro Val Ala Thr Ala Leu Asp Thr Ala Val Asp Val Phe Leu Cys
770 775 780

Ser Tyr Ile Ile Asp Pro Leu Asn Leu Phe Trp Phe Gly Ile Gly Lys
785 790 795 800

Ala Thr Val Phe Leu Leu Pro Ala Leu Ile Phe Ala Val Lys Leu Ala
805 810 815

Lys Tyr Tyr Arg Arg Met Asp Ser Glu Asp Val Tyr Asp Asp Val Glu
820 825 830

Thr Ile Pro Met Lys Asn Met Glu Asn Gly Asn Asn Gly Tyr His Lys
835 840 845

Asp His Val Tyr Gly Ile His Asn Pro Val Met Thr Ser Pro Ser Gln
850 855 860

His
865

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ BLACK BORDERS

☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.